Aptus Capital Advisors LLC Has $22.71 Million Stock Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Aptus Capital Advisors LLC increased its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 44.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 43,517 shares of the medical equipment provider's stock after purchasing an additional 13,367 shares during the quarter. Aptus Capital Advisors LLC's holdings in Intuitive Surgical were worth $22,714,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Bennett Selby Investments LP increased its stake in shares of Intuitive Surgical by 3.9% during the fourth quarter. Bennett Selby Investments LP now owns 449 shares of the medical equipment provider's stock worth $234,000 after purchasing an additional 17 shares during the period. Onefund LLC raised its position in Intuitive Surgical by 1.9% during the 4th quarter. Onefund LLC now owns 947 shares of the medical equipment provider's stock worth $494,000 after purchasing an additional 18 shares during the last quarter. LVW Advisors LLC raised its holdings in Intuitive Surgical by 1.3% during the 4th quarter. LVW Advisors LLC now owns 1,448 shares of the medical equipment provider's stock worth $756,000 after purchasing an additional 19 shares during the last quarter. Wesbanco Bank Inc. boosted its position in Intuitive Surgical by 1.6% during the fourth quarter. Wesbanco Bank Inc. now owns 1,216 shares of the medical equipment provider's stock valued at $635,000 after acquiring an additional 19 shares during the last quarter. Finally, FSM Wealth Advisors LLC boosted its position in shares of Intuitive Surgical by 3.7% during the 4th quarter. FSM Wealth Advisors LLC now owns 526 shares of the medical equipment provider's stock valued at $275,000 after purchasing an additional 19 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Intuitive Surgical news, EVP Myriam Curet sold 408 shares of the stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $589.75, for a total transaction of $240,618.00. Following the completion of the transaction, the executive vice president now directly owns 353 shares of the company's stock, valued at approximately $208,181.75. This trade represents a 53.61 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Jamie Samath sold 269 shares of the firm's stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $590.00, for a total transaction of $158,710.00. Following the transaction, the chief financial officer now owns 3,282 shares of the company's stock, valued at approximately $1,936,380. This trade represents a 7.58 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 33,313 shares of company stock worth $17,229,143 in the last quarter. 0.70% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on ISRG. Raymond James increased their target price on Intuitive Surgical from $560.00 to $688.00 and gave the stock an "outperform" rating in a report on Friday, January 24th. Royal Bank of Canada dropped their target price on shares of Intuitive Surgical from $630.00 to $605.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 23rd. UBS Group lifted their price target on Intuitive Surgical from $500.00 to $560.00 and gave the stock a "neutral" rating in a report on Monday, January 27th. Truist Financial reduced their target price on shares of Intuitive Surgical from $605.00 to $590.00 and set a "buy" rating for the company in a research report on Wednesday, April 23rd. Finally, Wells Fargo & Company boosted their target price on shares of Intuitive Surgical from $630.00 to $687.00 and gave the company an "overweight" rating in a report on Friday, January 24th. Five equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $598.95.

Intuitive Surgical Stock Performance

Intuitive Surgical stock traded up $8.35 during mid-day trading on Thursday, reaching $544.50. 649,463 shares of the company were exchanged, compared to its average volume of 1,623,167. The firm's 50-day simple moving average is $501.93 and its two-hundred day simple moving average is $534.44. Intuitive Surgical, Inc. has a twelve month low of $379.67 and a twelve month high of $616.00. The firm has a market cap of $195.16 billion, a PE ratio of 84.95, a price-to-earnings-growth ratio of 5.85 and a beta of 1.70.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.71 by $0.10. The company had revenue of $2.25 billion during the quarter, compared to analysts' expectations of $2.19 billion. Intuitive Surgical had a net margin of 27.81% and a return on equity of 14.55%. During the same quarter in the previous year, the business posted $1.50 earnings per share. As a group, equities research analysts anticipate that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.